Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 10.7% – Should You Sell?

Shares of Cel-Sci Corporation (NYSEAMERICAN:CVM) dropped 10.7% during trading on Friday . The stock traded as low as $4.80 and last traded at $4.91. Approximately 159,365 shares were traded during trading, an increase of 187% from the average daily volume of 55,565 shares. The stock had previously closed at $5.50.

Cel-Sci Stock Down 10.7%

The company has a current ratio of 0.47, a quick ratio of 0.37 and a debt-to-equity ratio of 0.89. The firm has a 50 day moving average price of $7.26 and a two-hundred day moving average price of $6.98. The firm has a market capitalization of $39.38 million, a price-to-earnings ratio of -0.50 and a beta of 0.49.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CVM. US Bancorp DE purchased a new stake in shares of Cel-Sci in the third quarter worth about $80,000. Bank of America Corp DE lifted its position in Cel-Sci by 2,188.2% during the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after acquiring an additional 39,190 shares in the last quarter. MAI Capital Management lifted its position in Cel-Sci by 229.9% during the 1st quarter. MAI Capital Management now owns 526,480 shares of the company’s stock worth $121,000 after acquiring an additional 366,880 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Cel-Sci by 59.7% in the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after acquiring an additional 109,352 shares during the period. 12.08% of the stock is owned by hedge funds and other institutional investors.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.